Simulations Plus Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Simulations Plus's estimated annual revenue is currently $10.2M per year.
- Simulations Plus's estimated revenue per employee is $145,000
- Simulations Plus has 70 Employees.
- Simulations Plus grew their employee count by 11% last year.
- Simulations Plus currently has 1 job openings.
What Is Simulations Plus?
Simulations Plus, Inc. (NASDAQ: SLP) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. We partner with companies to provide a data-driven, strategic modeling methodology, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. With our subsidiaries, Cognigen Corporation and DILIsym Services, we offer #1-ranked, easy-to-use software (GastroPlus, ADMET Predictor, KIWI, DILIsym®, NAFLDsym®, PKPlus, and more) to bridge data mining, compound library screening with QSAR models, PBPK/TK modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. Simulations Plus technology is licensed to and used by regulatory agencies worldwide. For over 20 years, Simulations Plus has partnered with our clients to reduce costs and accelerate research and development productivity by improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical & biotechnology agents. Simulations Plus team of over 80 dedicated scientists & professionals, with decades of experience, stands ready to help. For more information visit us at www.simulations-plus.comkeywords:Biotechnology,Healthcare,Human Resources Hr,Pharmaceuticals